Surveillance in ulcerative colitis: Is chromoendoscopy-guided endomicroscopy always better than conventional colonoscopy? a randomized trial

Inflammatory Bowel Diseases

Volumn 20, Issue 11, 2014, Pages 2038-2045

  Freire, Paulo ^a   Figueiredo, Pedro ^a,b   Cardoso, Ricardo ^a   Donato, Maria M ^b   Ferreira, Manuela ^a   Mendes, Sofia ^a   Silva, Mário R ^a   Cipriano, Augusta ^a   Ferreira, Ana M ^a   Vasconcelos, Helena ^c   Portela, Francisco ^a   Sofia, Carlos ^a,b  

^a CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c Hospital Santo André de Leiria   (Portugal)

Author keywords

Chromoendoscopy; Confocal laser endomicroscopy; Intraepithelial neoplasia; Surveillance; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID; AZATHIOPRINE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; COLORING AGENT; METHYLENE BLUE;

ADULT; ARTICLE; CANCER DIAGNOSIS; CHROMOENDOSCOPY; CHROMOENDOSCOPY GUIDED ENDOMICROSCOPY; COLONOSCOPY; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE DURATION; EVIDENCE BASED PRACTICE; FEMALE; HUMAN; HUMAN TISSUE; INTESTINE BIOPSY; INTESTINE CANCER; INTESTINE POLYP; INTRAEPITHELIAL NEOPLASIA; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; POLYPECTOMY; PREDICTIVE VALUE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SECONDARY ANALYSIS; SENSITIVITY AND SPECIFICITY; SMOKING; ULCERATIVE COLITIS; WHITE LIGHT ENDOSCOPY; CARCINOMA IN SITU; COLONIC NEOPLASMS; COMPLICATION; CONFOCAL MICROSCOPY; DIAGNOSTIC USE; EARLY DIAGNOSIS; ENDOSCOPY; FOLLOW UP; MIDDLE AGED; PATHOLOGY; PRECANCEROUS CONDITIONS; PROCEDURES; PROGNOSIS;

ADULT; CARCINOMA IN SITU; COLITIS, ULCERATIVE; COLONIC NEOPLASMS; COLONOSCOPY; COLORING AGENTS; EARLY DETECTION OF CANCER; ENDOSCOPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METHYLENE BLUE; MICROSCOPY, CONFOCAL; MIDDLE AGED; PRECANCEROUS CONDITIONS; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 84925640957     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000176     Document Type: Article

References (55)

1. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526-535.
2. Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2012;10:639-645.
3. Van Assche G, Dignass A, Bokemeyer B, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis. 2013;7:1-33.
4. Farraye FA, Odze RD, Eaden J, et al. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138:746-774.
5. Cairns SR, Scholefield JH, Steele RJ, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut. 2010;59:666-689.
6. Ransohoff DF, Riddell RH, Levin B. Ulcerative colitis and colonic cancer. Problems in assessing the diagnostic usefulness of mucosal dysplasia. Dis Colon Rectum. 1985;28:383-388.
7. Vieth M, Stolte M, Mueller E, et al. Bioptical differential diagnosis of adenomas, dysplasias and carcinomas in patients with ulcerative colitis. Leber Magen Darm. 2000;3:125-132.
8. Mattar MC, Lough D, Pishvaian MJ, et al. Current management of inflammatory bowel disease and colorectal cancer. Gastrointest Cancer Res. 2011;4:53-61.
9. Kandiel A. Colon cancer surveillance strategies in inflammatory bowel disease. Visible Hum J Endosc. 2008;7:21-25.
10. Harewood GC. Economic comparison of current endoscopic practices: Barrett's surveillance vs. ulcerative colitis surveillance vs. biopsy for sprue vs. biopsy for microscopic colitis. Dig Dis Sci. 2004;49:1808-1814.
11. Goetz M. Colonoscopic surveillance in inflammatory bowel disease: state of the art reduction of biopsies. Dig Dis. 2011;29:36-40.
12. van den Broek FJ, Stokkers PC, Reitsma JB, et al. Random biopsies taken during colonoscopic surveillance of patients with longstanding ulcerative colitis: low yield and absence of clinical consequences. Am J Gastroenterol. 2014;109:715-722.
13. Eaden JA, Ward BA, Mayberry JF. How gastroenterologists screen for colonic cancer in ulcerative colitis: an analysis of performance. Gastrointest Endosc. 2000;51:123-128.
14. Gearry RB, Wakeman CJ, Barclay ML, et al. Surveillance for dysplasia in patients with inflammatory bowel disease: a national survey of colonoscopic practice in New Zealand. Dis Colon Rectum. 2004;47:314-322.
15. Kaltz B, Bokemeyer B, Hoffmann J, et al. Surveillance colonoscopy in ulcerative colitis patients in Germany. Z Gastroenterol. 2007;45:325-331.
16. Ullman TA, Croog V, Harpaz N, et al. Biopsy specimen numbers in the routine practice of surveillance colonoscopy in ulcerative colitis (UC). Gastroentrology. 2004;126:A471.
17. Rodriguez SA, Eisen GM. Surveillance and management of dysplasia in ulcerative colitis by U.S. gastroenterologists: in truth, a good performance. Gastrointest Endosc. 2007;66:1070.
18. van Rijn AF, Fockens P, Siersema PD, et al. Adherence to surveillance guidelines for dysplasia and colorectal carcinoma in ulcerative and Crohn's colitis patients in the Netherlands. World J Gastroenterol. 2009;15:226-230.
19. Kiesslich R, Fritsch J, Holtmann M, et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology. 2003;124:880-888.
20. Matsumoto T, Nakamura S, Jo Y, et al. Chromoscopy might improve diagnostic accuracy in cancer surveillance for ulcerative colitis. Am J Gastroenterol. 2003;98:1827-1833.
21. Rutter MD, Saunders BP, Schofield G, et al. Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. Gut. 2004; 53:256-260.
22. Hurlstone DP, Sanders DS, Lobo AJ, et al. Indigo carmine-assisted highmagnification chromoscopic colonoscopy for the detection and characterisation of intraepithelial neoplasia in ulcerative colitis: a prospective evaluation. Endoscopy. 2005;37:1186-1192.
23. Kiesslich R, Goetz M, Lammersdorf K, et al. Chromoscopy-guided endomicroscopy increases the diagnostic yield of intraepithelial neoplasia in ulcerative colitis. Gastroenterology. 2007;132:874-882.
24. Marion JF, Waye JD, Present DH, et al. Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial. Am J Gastroenterol. 2008;103:2342-2349.
25. Günther U, Kusch D, Heller F, et al. Surveillance colonoscopy in patients with inflammatory bowel disease: comparison of random biopsy vs. targeted biopsy protocols. Int J Colorectal Dis. 2011;26:667-672.
26. Hlavaty T, Huorka M, Koller T, et al. Colorectal cancer screening in patients with ulcerative and Crohn's colitis with use of colonoscopy, chromoendoscopy and confocal endomicroscopy. Eur J Gastroenterol Hepatol. 2011;23:680-689.
27. Subramanian V, Mannath J, Ragunath K, et al. Meta-analysis: the diagnostic yield of chromoendoscopy for detecting dysplasia in patients with colonic inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33: 304-312.
28. Kiesslich R, Burg J, Vieth M, et al. Confocal laser endoscopy for diagnosing intraepithelial neoplasias and colorectal cancer in vivo. Gastroenterology. 2004;127:706-713.
29. Kiesslich R, Galle PR, Neurath MF. Endoscopic surveillance in ulcerative colitis: smart biopsies do it better. Gastroenterology. 2007;133:742-745.
30. Rispo A, Castiglione F, Staibano S, et al. Diagnostic accuracy of confocal laser endomicroscopy in diagnosing dysplasia in patients affected by longstanding ulcerative colitis. World J Gastrointest Endosc. 2012;4:414-420.
31. van den Broek FJ, van Es JA, van Eeden S, et al. Pilot study of probe-based confocal laser Endomicroscopy during colonoscopic surveillance of patients with longstanding ulcerative colitis. Endoscopy. 2011;43:116-122.
32. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol. 1989;170:2-6; discussion 16-19.
33. Sands BE. From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology. 2004;126: 1518-1532.
34. Podolsky DK. Inflammatory bowel disease (2). N Engl J Med. 1991;325: 1008-1016.
35. Walmsley RS, Ayres RC, Pounder RE, et al. A simple clinical colitis activity index. Gut. 1998;43:29-32.
36. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625-1629.
37. Paris Workshop Participants. The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. Gastrointest Endosc. 2003;58:S3-S43. Review.
38. Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012;6:965-990.
39. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012;6:991-1030.
40. Greenstein AJ, Sachar DB, Smith H, et al. Cancer in universal and leftsided ulcerative colitis: factors determining risk. Gastroenterology. 1979; 77:290-294.
41. Kiesslich R, Neurath MF. Chromoendoscopy: an evolving standard in surveillance for ulcerative colitis. Inflamm Bowel Dis. 2004;10:695-696.
42. Schlemper RJ, Riddell RH, Kato Y, et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut. 2000;47:251-255.
43. Hurlstone DP, McAlindon ME, Sanders DS, et al. Further validation of high-magnification chromoscopic-colonoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology. 2004;126:376-378.
44. Sada M, Igarashi M, Yoshizawa S, et al. Dye spraying and magnifying endoscopy for dysplasia and cancer surveillance in ulcerative colitis. Dis Colon Rectum. 2004;47:1816-1823.
45. Schulz KF, Altman DG, Moher D; for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomized trials. Open Med. 2010;4:60-68.
46. Soetikno RM, Lin OS, Heidenreich PA, et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc. 2002;56:48-54.
47. Efthymiou M, Taylor AC, Kamm MA. Cancer surveillance strategies in ulcerative colitis: the need for modernization. Inflamm Bowel Dis. 2011; 17:1800-1813.
48. Picco MF, Pasha S, Leighton JA, et al. Procedure time and the determination of polypoid abnormalities with experience: implementation of a chromoendoscopy program for surveillance colonoscopy for ulcerative colitis. Inflamm Bowel Dis. 2013;19:1913-1920.
49. Rutter MD, Saunders BP, Wilkinson KH, et al. Most dysplasia in ulcerative colitis is visible at colonoscopy. Gastrointest Endosc. 2004; 60:334-339.
50. Rubin DT, Rothe JA, Hetzel JT, et al. Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? Gastrointest Endosc. 2007;65:998-1004.
51. Blonski W, Kundu R, Lewis J, et al. Is dysplasia visible during surveillance colonoscopy in patients with ulcerative colitis? Scand J Gastroenterol. 2008;43:698-703.
52. Dixon MF, Brown LJ, Gilmour HM, et al. Observer variation in the assessment of dysplasia in ulcerative colitis. Histopathology. 1988;13: 385-397.
53. Noffsinger AE, Miller MA, Cusi MV, et al. The pattern of cell proliferation in neoplastic and nonneoplastic lesions of ulcerative colitis. Cancer. 1996;78:2307-2312.
54. Haritunians T, Taylor KD, Targan SR, et al. Genetic predictors of medically refractory ulcerative colitis. Inflamm Bowel Dis. 2010;16: 1830-1840.
55. Sjöberg D, Holmström T, Larsson M, et al. Incidence and natural history of ulcerative colitis in the Uppsala Region of Sweden 2005-2009-results from the IBD Cohort of the Uppsala Region (ICURE). J Crohns Colitis. 2013;7:e351-e357.